Compare DCTH & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | MYGN |
|---|---|---|
| Founded | 1988 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.5M | 444.2M |
| IPO Year | 2015 | 1996 |
| Metric | DCTH | MYGN |
|---|---|---|
| Price | $12.59 | $5.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $22.00 | $7.64 |
| AVG Volume (30 Days) | 579.8K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $24.54 | $6.86 |
| Revenue Next Year | $33.15 | $5.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $8.12 | $3.53 |
| 52 Week High | $13.44 | $8.59 |
| Indicator | DCTH | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 72.85 |
| Support Level | $10.26 | $4.29 |
| Resistance Level | N/A | $7.29 |
| Average True Range (ATR) | 0.57 | 0.34 |
| MACD | 0.12 | 0.16 |
| Stochastic Oscillator | 76.05 | 87.53 |
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.